Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. NLRP3 compound I-19
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. NLRP3 compound I-19: sourced facts only. name: "Both I-19 and II-8 bind to the LRR domain, inhibiting NLRP3 inflammasome activation." [PMID:38888047]; target: "Both I-19 and II-8 bind to the LRR domain, inhibiting NLRP3 inflammasome activation." [PMID:38888047]; developer: "Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China." [PMID:38888047]; stage: "Compound I-19 from the initial series effectively inhibited caspase-1 and IL-1β release in an adjuvant-induced arthritis (AIA) rat model, significantly reducing joint swelling and spleen/thymus indices." [PMID:38888047]
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on China Pharma Univ. NLRP3 compound I-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. NLRP3 compound I-19.